Sugi Predict

Sugi Predict / Compounds / SCHEMBL107422

SCHEMBL107422

SCHEMBL107422

CC(=O)C(Cc1ccccc1)Cc1ccccc1.[Pd]

nearest known ligand 0.65

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ CYP1A2 P05177 1/20 0.65
▸ CPA1 P15085 5/20 0.57
▸ CPA3 P15088 3/20 0.57
▸ FOLH1 Q04609 1/20 0.57
▸ CPB1 P15086 1/20 0.57
▸ CPB2 Q96IY4 1/20 0.57
▸ ALPI P09923 1/20 0.55
▸ PKM P14618 1/20 0.55
▸ PTGS1 P23219 1/20 0.55
▸ XIAP P98170 1/20 0.55
▸ SLC7A5 Q01650 1/20 0.55
▸ SLC15A1 P46059 1/20 0.52
▸ SLC1A3 P43003 1/20 0.52
▸ SLC1A2 P43004 1/20 0.52
▸ SLC1A1 P43005 1/20 0.52
▸ LTA4H P09960 2/20 0.51
▸ MME P08473 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4451600 1.00 CYP1A2 (0.65) CYP1A2CPA1CPA3FOLH1CPB1
SCHEMBL4724923 1.00 CYP1A2 (0.65) CYP1A2CPA1CPA3FOLH1CPB1
SCHEMBL40705 1.00 CYP1A2 (0.65) CYP1A2CPA1CPA3FOLH1CPB1
SCHEMBL29865739 1.00 CYP1A2 (0.65) CYP1A2CPA1CPA3FOLH1CPB1
SCHEMBL2588080 1.00 CYP1A2 (0.65) CYP1A2CPA1CPA3FOLH1CPB1
SCHEMBL497369 0.98 CYP1A2 (0.68) CYP1A2CPA1CPA3FOLH1CPB1
SCHEMBL28912638 0.96 CYP1A2 (0.65) CYP1A2CPA1CPA3FOLH1CPB1
Chloroform SCHEMBL29063596 0.94 CYP1A2 (0.59) CYP1A2CPA1CPA3FOLH1CPB1
SCHEMBL21895912 0.88 CYP1A2 (0.67) CYP1A2CPA1CPA3FOLH1CPB1
SCHEMBL11634382 0.88 CYP1A2 (0.67) CYP1A2CPA1CPA3FOLH1CPB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 146 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025119663-A1 HERBICIDAL DERIVATIVES SYNGENTA CROP PROTECTION AG (CH) 2025-06-12 — — WO disclosed
US-20200339577-A1 1-SUBSTITUTED 1,2,3,4-TETRAHYDRO-1,7-NAPHTHYRIDIN-8-AMINE DERIVATIVES AND THEIR USE AS EP4 RECEPTOR ANTAGONISTS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2020-10-29 — — US disclosed
CN-110483571-B (1- (substituted phenyl) acenaphthenyl) -bis (3, 5-bis (trifluoromethyl)) phenylphosphine compound and preparation method thereof 中国科学技术大学 2020-10-27 — — CN disclosed
US-10745397-B2 1-Substituted 1,2,3,4-tetrahydro-1,7-naphthyridin-8-amine derivatives and their use as EP4 receptor antagonists TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2020-08-18 — — US disclosed
EP-3325490-B1 1-SUBSTITUTED 1,2,3,4-TETRAHYDRO-1,7-NAPHTHYRIDIN-8-AMINE DERIVATIVES AND THEIR USE AS EP4 RECEPTOR ANTAGONISTS TAKEDA PHARMACEUTICALS CO (JP) 2019-12-18 — — EP disclosed
US-20180215754-A1 1-SUBSTITUTED 1,2,3,4-TETRAHYDRO-1,7-NAPHTHYRIDIN-8-AMINE DERIVATIVES AND THEIR USE AS EP4 RECEPTOR ANTAGONISTS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2018-08-02 — — US disclosed
EP-3325490-A1 1-SUBSTITUTED 1,2,3,4-TETRAHYDRO-1,7-NAPHTHYRIDIN-8-AMINE DERIVATIVES AND THEIR USE AS EP4 RECEPTOR ANTAGONISTS Takeda Pharmaceutical Company Limited (JP) 2018-05-30 — — EP disclosed
WO-2017014323-A1 1-SUBSTITUTED 1,2,3,4-TETRAHYDRO-1,7-NAPHTHYRIDIN-8-AMINE DERIVATIVES AND THEIR USE AS EP4 RECEPTOR ANTAGONISTS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2017-01-26 — — WO disclosed
CN-104263351-B Luminescent material based on thiaanthracene-fluorene spiro-structure and organic photoelectric device taking material as luminescent layer SOUTH CHINA UNIVERSITY OF TECHNOLOGY (CN) 2017-01-04 — — CN disclosed
WO-2016088903-A1 HETEROCYCLIC COMPOUNDS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-06-09 — — WO disclosed
EP-1280764-A2 INHIBITORS OF HISTONE DEACETYLASE Methylgene, Inc. (CA) 2003-02-05 — — EP disclosed
US-20020115826-A1 Inhibitors of histone deacetylase 92229129 QUEBEC INC. (CA) 2002-08-22 — — US disclosed
WO-2001070675-A2 INHIBITORS OF HISTONE DEACETYLASE METHYLGENE, INC. (CA) 2001-09-27 — — WO disclosed
EP-1105366-A1 DIVINYLSTILBENESULFONIC ACID DERIVATIVES Ciba SC Holding AG (CH) 2001-06-13 — — EP disclosed
WO-2001010854-A1 BENZOTHIAZOLE COMPOUNDS AND THEIR USE AS OPTICAL BRIGHTENERS CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) 2001-02-15 — — WO disclosed
CN-1251056-A Prepn. of catalyst SHELL INT RESEARCH (NL) 2000-04-19 — — CN disclosed
WO-2000009471-A1 DIVINYLSTILBENESULFONIC ACID DERIVATIVES CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) 2000-02-24 — — WO disclosed
CN-1241188-A Heterocyclylmethyl-substed pyrazol derivs. BAYER AG (DE) 2000-01-12 — — CN disclosed
EP-0589527-B1 Polymerization process MONTELL TECHNOLOGY COMPANY BV (NL) 1999-07-28 — — EP disclosed
EP-0589527-A1 Polymerization process SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) 1994-03-30 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10745397-B2 1-Substituted 1,2,3,4-tetrahydro-1,7-naphthyridin-8-amine derivatives and their use as EP4 receptor antagonists PTGER4, PTGER1, PTGER3 CYP1A2 1070/4885CPA1 3708/4885CPA3 3796/4885
US-20200339577-A1 1-SUBSTITUTED 1,2,3,4-TETRAHYDRO-1,7-NAPHTHYRIDIN-8-AMINE DERIVATIVES AND THEIR USE AS EP4 RECEPTOR ANTAGONISTS PTGER4, PTGER1, PTGER3 CYP1A2 1070/4885CPA1 3708/4885CPA3 3796/4885
US-20020115826-A1 Inhibitors of histone deacetylase HDAC1, HDAC5, HDAC3 CYP1A2 4430/4885CPA1 2612/4885CPA3 2587/4885
US-20180215754-A1 1-SUBSTITUTED 1,2,3,4-TETRAHYDRO-1,7-NAPHTHYRIDIN-8-AMINE DERIVATIVES AND THEIR USE AS EP4 RECEPTOR ANTAGONISTS PTGER4, PTGER1, PTGER3 CYP1A2 1070/4885CPA1 3708/4885CPA3 3796/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.